The Mechanism of MSCs Therapy in Acute Respiratory Distress SyndromeYing Wang, Cuicui Chen, Dongni Hou and Yuanlin Song*
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, China
- Corresponding Author:
- Song Y
Department of Pulmonary Medicine
Zhongshan Hospital, Fudan University
180 Fenglin Road, Shanghai, China
E-mail: [email protected]
Received Date: December 18, 2015; Accepted Date: April 25, 2016; Published Date: April 30, 2016
Citation: Wang Y, Chen C, Hou D, Song Y (2016) The Mechanism of MSCs Therapy in Acute Respiratory Distress Syndrome. J Clin Respir Dis Care 2:115. doi: 10.4172/2472-1247.1000115
Copyright: © 2016 Wang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In past decades, acute respiratory distress syndrome (ARDS) has been associated with high mortality and morbidity. Although many maneuvers have been tested including tens of clinical trials, so far there is still no approved pharmacological intervention available for ARDS except protective ventilation strategy. Mesenchymal stem cells (MSCs) has shown improved survival in various ARDS animal model after administration. Here we summarized the updates of MSC derivation and purification, administration approaches, timing of MSC delivery, and mechanism of MSC therapy in order to provide a state-of-art paradigm of cell based therapy in ARDS and to facilitate the development of MSC therapy in ARDS patients.